溶瘤病毒免疫療法市場規模、佔有率和成長分析：按治療方法、適應症、給藥途徑、最終用戶、分銷管道和地區分類－2026-2033年產業預測

2024 年全球溶瘤病毒免疫療法市值為 18.4 億美元，預計到 2025 年將成長至 20.7 億美元，到 2033 年將成長至 54 億美元，在預測期（2026-2033 年）內複合年成長率為 12.6%。

全球溶瘤病毒免疫療法市場的主要驅動力是基因工程和腫瘤免疫學技術的融合，這使得實驗性藥物轉化為有效的治療方法。溶瘤病毒透過選擇性地靶向並摧毀癌細胞，同時增強全身性抗腫瘤免疫反應，彌合了病毒學和腫瘤學之間的鴻溝。這種雙重作用機制克服了傳統治療方法的限制。創新已從天然病毒分離株發展到基因改造平台，並透過成功的臨床試驗和核准展現出巨大的商業性潛力。關鍵的成長要素之一是與免疫查核點抑制劑的協同作用，有助於調節腫瘤微環境並提高治療反應性。此外，人工智慧技術正在透過標靶選擇和載體設計最佳化，加速適應性臨床試驗計畫的製定，並建立夥伴關係，從而改善生產流程並加速市場准入，從而革新臨床開發。

全球溶瘤病毒免疫療法市場促進因素

全球溶瘤病毒免疫療法市場正受到病毒載體工程領域重大進展的推動。這些進展顯著提高了標靶化腫瘤和遞送治療基因的能力。這些創新使得開發具有更高特異性和免疫抗原性的溶瘤藥物成為可能，從而最大限度地減少了脫靶效應並擴大了治療應用範圍。此類技術進步正在推動臨床開發工作，並增強研究人員的信心。此外，病毒親和性和所攜帶基因的客製化能力使得開發針對不同腫瘤類型和患者特徵的個人治療方法成為可能，最終激發了研發人員的興趣，並有助於建立一個充滿活力的新型治療方法研發管線，從而推動市場成長。

全球溶瘤病毒免疫療法市場的限制因素

全球溶瘤病毒免疫療法市場面臨許多挑戰，其中生物活性病毒的生產極其複雜，這限制了市售產品的供應，並增加了研發風險。複雜的上游和下游製程需要專門的設施和嚴格的品管來維持病毒的效力和穩定性，這構成了新進入者的主要准入門檻，並推高了營運成本。此外，對熟練人員和客製化生產流程的需求也會阻礙企業及時進入市場，並影響潛在的投資。同時，供應鏈的脆弱性和生產批次的差異性也阻礙了醫療機構的廣泛應用，並限制了他們滿足日益成長的患者需求的能力。

全球溶瘤病毒免疫療法市場趨勢

全球溶瘤病毒免疫療法市場正經歷著向個人化聯合治療的顯著轉變。人們對腫瘤異質性和個別患者獨特免疫環境的認知不斷提高，正在重塑溶瘤病毒的治療方法。研發人員日益專注於建構整合免疫調節劑和標靶治療的個人化治療方法，採用適應性策略，根據每位患者的特定生物學特徵和病歷調整病毒選擇、劑量和治療方法。這項轉變凸顯了基於生物標記的患者篩選和轉化研究的重要性，確保臨床方案的設計靈活且嚴謹，從而在保證安全性的前提下最佳化治療效果。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球溶瘤病毒免疫療法市場規模：依治療方法分類

• 單純皰疹病毒治療方法
• 基於腺病毒的治療方法
• 痘病毒和呼腸孤病毒療法
• 新城疫病毒療法
• 其他

全球溶瘤病毒免疫療法市場規模：依適應症分類

• 黑色素瘤和皮膚癌
• 乳癌和肺癌
• 前列腺癌和膀胱癌
• 頭頸部鱗狀細胞癌
• 其他

全球溶瘤病毒免疫療法市場規模：依給藥途徑分類

• 腫瘤內注射
• 靜脈注射
• 其他

全球溶瘤病毒免疫療法市場規模：以最終用戶分類

• 專科癌症中心
• 醫院和診所
• 研究和學術機構
• 其他

全球溶瘤病毒免疫療法市場規模：按分銷管道分類

• 醫院藥房
• 專科藥房
• 線上醫療平台
• 其他

全球溶瘤病毒免疫療法市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Amgen
• Merck & Co.
• Roche
• Replimune
• Oncos Therapeutics
• Oncolytics Biotech
• Oncorus
• Sorrento Therapeutics
• Transgene
• PsiOxus Therapeutics
• Genelux
• Vyriad
• CG Oncology
• Virogin Biotech
• IconOVir Bio
• Lokon Pharma
• Targovax
• SillaJen
• ImmVirX
• KalVista Pharmaceuticals

結論與建議

Global Oncolytic Virus Immunotherapy Market size was valued at USD 1.84 Billion in 2024 and is poised to grow from USD 2.07 Billion in 2025 to USD 5.4 Billion by 2033, growing at a CAGR of 12.6% during the forecast period (2026-2033).

The global oncolytic virus immunotherapy market is predominantly driven by the integration of advancements in genetic engineering and immuno-oncology, transforming experimental agents into effective therapies. Oncolytic viruses selectively target and destroy tumor cells while simultaneously enhancing systemic antitumor immune responses, bridging virology and oncology. This dual-action mechanism addresses limitations of traditional treatments. Innovations have evolved from natural viral isolates to engineered platforms, demonstrating significant commercial potential through successful trials and approvals. A key growth factor is the synergy with immune checkpoint inhibitors that enhances tumor microenvironment modulation, leading to improved treatment responsiveness. Furthermore, AI technologies are revolutionizing clinical development by optimizing target selection and vector design, facilitating adaptive trial planning, and fostering partnerships that refine manufacturing processes and accelerate market entry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Oncolytic Virus Immunotherapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Oncolytic Virus Immunotherapy Market Segments Analysis

Global oncolytic virus immunotherapy market is segmented by therapy type, indication, route of administration, end-user, distribution channel and region. Based on therapy type, the market is segmented into Herpes Simplex Virus-Based Therapy, Adenovirus-Based Therapy, Poxvirus and Reovirus Therapy, Newcastle Disease Virus Therapy and Others. Based on indication, the market is segmented into Melanoma and Skin Cancers, Breast and Lung Cancer, Prostate and Bladder Cancer, Head and Neck Squamous Cell Carcinoma and Others. Based on route of administration, the market is segmented into Intratumoral Injection, Intravenous Infusion and Others. Based on end-user, the market is segmented into Specialized Cancer Centers, Hospitals and Clinics, Research and Academic Institutes and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Specialty Pharmacies, Online Healthcare Platforms and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Oncolytic Virus Immunotherapy Market

The Global Oncolytic Virus Immunotherapy market is being propelled by significant advancements in viral vector engineering, which have markedly improved tumor targeting and the delivery of therapeutic genes. These innovations allow for the development of oncolytic agents that possess enhanced specificity and immunogenicity, thereby minimizing off-target effects and expanding the therapeutic window. Such technical improvements bolster clinical development efforts and instill greater confidence among researchers. Furthermore, the ability to customize viral tropism and payloads enables the creation of tailored therapies for various tumor types and patient profiles, ultimately stimulating interest among developers and contributing to a dynamic pipeline of novel treatments that drive market growth.

Restraints in the Global Oncolytic Virus Immunotherapy Market

The Global Oncolytic Virus Immunotherapy market faces significant challenges due to the high complexity of manufacturing biologically active viruses, which restricts commercial availability and increases development risks. The intricate upstream and downstream processes involved demand specialized facilities and rigorous quality controls to maintain potency and consistency, thereby creating substantial barriers for new market entrants and elevating operational costs. Additionally, the requirement for skilled personnel and tailored manufacturing workflows can impede timely market entry and deter potential investments. Furthermore, supply chain vulnerabilities and variability in production batches hinder widespread adoption by healthcare providers and limit the capacity to fulfill growing patient demand.

Market Trends of the Global Oncolytic Virus Immunotherapy Market

The Global Oncolytic Virus Immunotherapy market is experiencing a significant trend towards personalized combination therapies. There is a growing recognition of tumor heterogeneity and the unique immune landscapes of individual patients, which is reshaping the approach to oncolytic virus treatments. Developers are increasingly focused on creating tailored regimens that integrate immune modulators and targeted agents, employing adaptive strategies that align virus selection, dosing, and therapeutic combinations with the specific biology and history of each patient's disease. This shift underscores the importance of biomarker-driven patient selection and translational research, ensuring that clinical protocols are both flexible and meticulously designed to optimize therapeutic outcomes while maintaining safety.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Oncolytic Virus Immunotherapy Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Herpes Simplex Virus-Based Therapy
• Adenovirus-Based Therapy
• Poxvirus and Reovirus Therapy
• Newcastle Disease Virus Therapy
• Others

Global Oncolytic Virus Immunotherapy Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Melanoma and Skin Cancers
• Breast and Lung Cancer
• Prostate and Bladder Cancer
• Head and Neck Squamous Cell Carcinoma
• Others

Global Oncolytic Virus Immunotherapy Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intratumoral Injection
• Intravenous Infusion
• Others

Global Oncolytic Virus Immunotherapy Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Specialized Cancer Centers
• Hospitals and Clinics
• Research and Academic Institutes
• Others

Global Oncolytic Virus Immunotherapy Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies
• Online Healthcare Platforms
• Others

Global Oncolytic Virus Immunotherapy Market Size & CAGR (2026-2033)

• North America (Therapy Type, Indication, Route of Administration, End-User, Distribution Channel)
  • US
  • Canada
• Europe (Therapy Type, Indication, Route of Administration, End-User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Indication, Route of Administration, End-User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Indication, Route of Administration, End-User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Indication, Route of Administration, End-User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Amgen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Replimune
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oncos Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oncolytics Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oncorus
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sorrento Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Transgene
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PsiOxus Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genelux
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vyriad
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CG Oncology
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virogin Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IconOVir Bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lokon Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Targovax
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SillaJen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ImmVirX
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KalVista Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations